BACKGROUND: E2V/DNG is widely use in Russian clinical practice, although satisfaction of Russian patients and doctors has not been ever evaluated and analysed.
AIM: To evaluate satisfaction in young women (18–35 years old) with a drug containing estradiol valerate/dienogest (E2V/ DNG) over a 6-month period in real clinical practice in Russia.
MATERIALS AND METHODS: This was a prospective multicenter study (Q-SWAN – Qlaira, Satisfaction, WomAN [ClinicalTrials. gov: NCT04901377]) that assessed satisfaction of 504 women (average age is 27.8 years) with the contraceptive containing E2V/DNG. The characteristics of menstrual bleeding, sexual function, women’s decision to continue and satisfaction of doctors with this method of contraception were also assessed.
RESULTS: It was found that 98.4% of women and 100% of doctors were “very satisfied” or “satisfied” with this method of contraception, regardless of the presence or absence of AUB. There was a significant decrease in the intensity, duration of menstrual bleeding and pain. Normalization of the parameters of the FSFI questionnaire was observed in most of the patients (89.7%). The contraceptive E2V/DNG was well tolerated by women, and the overall rate of adverse events was 7.1%. Most women (97.8%) decided to continue taking the medication after completing the study.
CONCLUSION: The results of the study showed high satisfaction of young Russian women and doctors with the use of E2V/DNG, regardless of the presence or absence of AUB. The medication has a positive effect on the characteristics of bleeding/ cycle control and on the quality of sexual function, therefore, the women demonstrated a high adherence to this method of contraception.

This issue of reproductive medicine news presents current research and data from reviews and meta-analyses on the study and innovative methods of treating diseases of the reproductive system, presented in leading international periodicals

On November 3, 2024, professor of the Cathedra of Obstetrics, Gynecology and Reproductive Medicine of the Russian University of Medicine, Doctor of Medical Sciences, prominent scientist, lecturer and doctor Marianna A. Gevorkyan died at the age of 68

The 9^th the All-Russian International Reproductive Health Conference has been provided in the period from 26^th October, 2024 until 27^th October, 2024 in the Endocrinology Research Centre (Moscow, Russian Federation), The aim of conference was choice of gold standard way for maintenance of female and male reproductive health of the 21^st century. 421 sessions, 1 plenary lecture, 108 presentations, 1 plenary meeting, 8 symposiums, 5 scientific sessions, have been provided. 23149 online participants from 45 world countries and 421 real-time participants from 15 Russian regions and 2 post-Soviet countries joined. The special accent was mentioned during discussion about innovative approaches for diagnostics, treatment and prevention of reproductive diseases. The present conference has been organized according to provided by Russian president Vladimir Putin Year of Family 2024 and 2^nd International Metabolic Disease Congress (10^th-12^th October, 20021, Moscow, Russia).